Suchergebnisse - "Denkert, C"

PubPharm (224)

1

Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)

enthalten in: ESMO open | 2024

von Meyer-Wilmes, P. | Huober, J. | Untch, M. | +21

2

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC : exploratory analysis from KEYNOTE-522

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Pusztai, L. | Denkert, C. | O'Shaughnessy, J. | +16

3

Early breast cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Loibl, S. | André, F. | Bachelot, T. | +38

4

Understanding breast cancer complexity to improve patient outcomes : The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Curigliano, G. | Burstein, H. | Gnant, M. | +79

5

ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Loibl, S. | Azim, H. | Bachelot, T. | +21

6

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Tarantino, P. | Viale, G. | Press, M. | +29

CommentIn: Ann Oncol. 2023 Oct;34(10):948-949. - PMID 37499869

7

Long-term survival of breast cancer patients with brain metastases : subanalysis of the BMBC registry

enthalten in: ESMO open | 2023

von Riecke, K. | Müller, V. | Neunhöffer, T. | +18

8

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

enthalten in: ESMO open | 2022

von Schmidt, M. | Lübbe, K. | Decker, T. | +16

9

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Loibl, S. | Schneeweiss, A. | Huober, J. | +17

CommentIn: Ann Oncol. 2022 Nov;33(11):1091-1093. - PMID 36096335

10

Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer : clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Loibl, S. | Untch, M. | Burchardi, N. | +20

ErratumFor: Ann Oncol. 2019 Aug 1;30(8):1279-1288. - PMID 31095287

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[23]